Miniatura

Fitxers

730797.pdf (196.15 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-09-09

Llicència de publicació

cc by-nc (c) Rodríguez Espinosa, Diana, 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/200385

Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1159/000526368

Resum

Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cause of end-stage kidney disease. Currently, tolvaptan is the only treatment that has proven to delay disease progression. The most notable side effect of this therapy is drug-induced liver injury; however, recently, there have been two reports of creatine kinase (CK) elevation in ADPKD patients on tolvaptan treatment. We set out to monitor and determine the actual incidence of CK elevation and evaluate its potential association with other clinical factors. Methods: This is an observational retrospective multicenter study performed in rapidly progressive ADPKD patients on tolvaptan treatment from Barcelona, Spain. Laboratory tests, demographics, treatment dose, and reported symptoms were collected from October 2018 to March 2021. Results: Ninety-five patients initiated tolvaptan treatment during follow-up. The medication had to be discontinued in 31 (32.6%) patients, primarily due to aquaretic effects (12.6%), elevated liver enzymes (8.4%), and symptomatic or persistently elevated CK levels (3.2%). Moreover, a total of 27 (28.4%) patients had elevated CK levels, with most of them being either transient (12.6%), mild and asymptomatic (4.2%), or resolved after dose reduction (3.2%) or temporary discontinuation (2.1%). Conclusion: We pre-sent the largest cohort that has monitored CK levels in a real-life setting, finding them elevated in 28.4% of patients. More research and monitoring will help us understand the clinical implications and the pathophysiological mechanism of CK elevation in this population.

Matèries

Creatina quinasa, Malalties del ronyó, Efectes secundaris dels medicaments, Quistos

Matèries (anglès)

Creatine kinase, Kidney diseases, Drug side effects, Cysts (Pathology)

Citació

Col·leccions

Articles publicats en revistes (Medicina)

Citació

RODRÍGUEZ ESPINOSA, Diana, BROSETA, José jesús, BASTIDA, Carla, ÁLVAREZ MORA, María isabel, NICOLAU, Carlos, ÁLVAREZ, Cristina, AGRAZ, Irene, SÁNCHEZ BAYA, Maya, FURLANO, Monica, RUIZ, César, QUINTANA PORRAS, Luis f., PIÑEIRO, Gastón julio, POCH LÓPEZ DE BRIÑAS, Esteban, TORRA, Roser, BLASCO PELICANO, Miquel. Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment. _Nephron_. 2022. Vol. 147, núm. 3-4, pàgs. 152-157. [consulta: 29 de abril de 2026]. ISSN: 1660-8151. [Disponible a: https://hdl.handle.net/2445/200385]

Exportar metadades

JSON - METS

Compartir registre